JNJ-5322

JNJ-5322 (also known as JNJ-80945322) is a next-generation trispecific antibody designed for the treatment of relapsed or refractory multiple myeloma. It simultaneously targets two validated myeloma antigens, B-cell maturation antigen (BCMA) and G protein-coupled receptor class C group 5 member D (GPRC5D), while engaging the CD3 receptor on T-cells. This trispecific architecture is intended to enhance antitumor activity by addressing tumor heterogeneity and reducing the risk of resistance due to antigen escape, which are common limitations of mono-targeting bispecific antibodies. Developed by Johnson & Johnson, JNJ-5322 is administered subcutaneously and has demonstrated potent T-cell mediated cytotoxicity and high overall response rates in early-phase clinical trials.